Introduction
The article discusses the implementation of universal breast cancer care in Mexico, focusing on the significance of Related Diagnosis Groups (GRD) and a compensation chamber to ensure effective, timely treatment for all women, regardless of their social security status.
Background and Previous Successes
Under the Seguro Popular program, Mexico witnessed a substantial reduction in the treatment gap for breast cancer among women without social security, falling from 0.71 in 2007 to 0.15 by 2016. This success was attributed to explicit funding, clear payment rules, and accredited treatment centers. The five-year survival rate was 72.2% overall and 89.0% for early-stage breast cancer, although 65% of patients started treatment in advanced stages, highlighting the importance of early diagnosis and timely treatment.
GRD and FPGC: Existing Tools for Universal Care
The Imss’s GRD already possess a Medical-Economic Certificate (CME) and a Reference Medical-Technical Cost (CMTR), which reflect the average hospitalization cost. These elements can be used to construct case-based tariffs, adjustable for case mix, severity, and comorbidities. This framework is compatible with existing GRD tariff catalogs in other public institutions, such as Pemex and the Mexico City Health Services, which include oncological procedures and radiation therapy under standardized codes and descriptions.
How a Compensation Chamber with FONSABI Could Function
1. Explicit Budget and Unique Clinical Pathway
Combine all breast cancer care components into a single service line, including risk-based screening, clinical examination, diagnostic imaging (mamography, ultrasound), biopsy with core needle, pathology with immunohistochemistry (ER, PR, HER2), staging, surgery (including sentinel lymph node biopsy), chemotherapy, radiation therapy, and hormone therapy. Additionally, patient navigation and key timelines (e.g., ≤30 days from diagnosis to treatment) should be included.
2. Case-Based Payment with GRD/FPGC
For each episode (e.g., “Stage I-II breast cancer with conservative surgery and radiation therapy”), FONSABI would pay a base tariff derived from the GRD CMTR, multiplied by a case-mix index (CMI), adjusted for severity and comorbidities, and including a quality component (bonuses/penalties) for timely diagnosis, biomarker identification, sentinel lymph node use, and adherence to guidelines.
3. FONSABI Compensation Chamber
A central hub that receives standardized claims (GRD + clinical codes), validates them based on clinical appropriateness, cost, and timeliness, calculates the amount, and compensates between institutions (IMSS, IMSS-Bienestar, ISSSTE, state social security, and both public and private sectors) regardless of where the patient was treated.
4. Transparency and Control
All claims are traceable by GRD, stage, and key timelines. The claim bases allow monitoring gaps, survival rates, and unjustified variations by state and hospital type.
Infrastructure and Decision-Making for the Future
Approximately 99 cities with ≥100,000 inhabitants have the necessary infrastructure for comprehensive breast cancer care (diagnosis, pathology with IHQ, oncological surgery, chemotherapy, and radiation therapy). Mexico should decide on the GRD basket and episodes by stage and therapeutic modality, linked to IMSS’s CMTR/CME. FONSABI should issue payment rules with the formula: Payment = CMTR × CMI × (1±Quality), including caps and “stop-loss” for atypical cases. Accredit and publish the network per city (≥100,000) and metropolitan area, specifying local and referral components and maximum timelines.
Audit traced results, including diagnostic-to-treatment times, treatment initiation, IHQ completeness, and stage-specific survival rates. Update and harmonize tariffs using public GRD catalogs (e.g., Pemex) for radiation therapy and related procedures as references. Inventory the complementary oncological services in social and private sectors.
Conclusion
The proposed compensation chamber does not invent new concepts; it organizes and makes interoperable proven Mexican components—GRD with CMTR/CME, case-based packages similar to FPGC, and public tariff catalogs—to translate federal announcements into earlier diagnosis, timely treatment, and outcome-based payments in the 55 cities with comprehensive capabilities. This is the shortest path from rhetoric to survival.
